Regencell Bioscience Holdings Limited (RGCB)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -812,371 |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering.
Regencell Bioscience has filed to go public with an IPO on the NASDAQ.
About RGCB
Regencell Bioscience is an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (\"TCM\") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”). Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We have three standardized TCM formulae candidates u... [Read more...]
| Industry Medicinal Chemicals & Botanical Products | IPO Date Pending |
| CEO Yat-Gai Au | Country Hong Kong |
| Stock Exchange NASDAQ | Ticker Symbol RGCB |